MedTrace Logo

The Efficacy and Safety of Dabigatran Etexilate for the Treatment of Cerebral Venous Thrombosis

NCT03217448 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2017-11-22

No results posted yet for this study

Summary

This is a single-center, prospective, randomized (1:1), open-label study with two parallel groups. This study is planned to investigate the efficacy and safety of dabigatran etexilate comparing with warfarin for the treatment of cerebral venous thrombosis.

Conditions

  • Cerebral Venous Thrombosis

Interventions

DRUG

Dabigatran etexilate

Subjects should take Dabigatran etexilate 150mg twice a day for 6 months after randomization.

DRUG

Warfarin

Subjects should take Warfarin for 6 months after randomization and the dose will be changed according to investigator's judgment.

Sponsors & Collaborators

  • Capital Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-30
Primary Completion
2019-01-31
Completion
2019-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03217448 on ClinicalTrials.gov